"These assays enable preclinical risk assessment of gene therapy vectors, potentially paving the way for safer gene therapy vectors used in clinical trials." AVROBIO uses these assays to inform vector selection during preclinical development. In addition, to date, AVROBIO has seen no cases of insertional oncogenesis in any of its clinical programs. "Safety is at the forefront of our work at AVROBIO and incorporated in the development of our plato® platform, which includes our advanced vector design, optimized for safety as well as transgene expression and protein uptake," said AVROBIO President and CEO Geoff MacKay. "Combining these assays helps assess vector genotoxicity risk early in preclinical development and further reaffirms that not all lentiviral vectors are designed the same."